# Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)

Study · id `cardio:ct-nct01630278` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01630278](<https://clinicaltrials.gov/study/NCT01630278>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01630278

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

## Technical summary

Registry record NCT01630278. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (actual); primary completion 2019-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 363 participants (enrolled count; ClinicalTrials.gov record NCT01630278, source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)
- Started: 2012-03 (actual) (ClinicalTrials.gov record NCT01630278, source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2019-06 (actual) (ClinicalTrials.gov record NCT01630278, source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)
- Completion: 2019-06 (actual) (ClinicalTrials.gov record NCT01630278, source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT01630278, source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01630278-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
- Acronym: TRIOCAPI
- Condition: Patent Ductus Arteriosus
- Intervention (Drug): Ibuprofen
- Intervention (Drug): Placebo
- Lead sponsor: Nantes University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Nantes University Hospital (`cardio:org-nantes-university-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial (`cardio:pubmed-33307111`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e608d4bb4824a20d90bc3883b3f274c321a0c6a0e2cd88022bf487fe0385a274
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
